[go: up one dir, main page]

DE69530368D1 - Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung - Google Patents

Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung

Info

Publication number
DE69530368D1
DE69530368D1 DE69530368T DE69530368T DE69530368D1 DE 69530368 D1 DE69530368 D1 DE 69530368D1 DE 69530368 T DE69530368 T DE 69530368T DE 69530368 T DE69530368 T DE 69530368T DE 69530368 D1 DE69530368 D1 DE 69530368D1
Authority
DE
Germany
Prior art keywords
vinca alkaloid
tumor targeting
vesicle
increased effectiveness
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69530368T
Other languages
English (en)
Other versions
DE69530368T2 (de
Inventor
Eric Forssen
Gerry W Cox
Denniss Hair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexstar Pharmaceuticals Inc
Original Assignee
Nexstar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexstar Pharmaceuticals Inc filed Critical Nexstar Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69530368D1 publication Critical patent/DE69530368D1/de
Publication of DE69530368T2 publication Critical patent/DE69530368T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
DE69530368T 1994-06-27 1995-06-27 Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung Expired - Lifetime DE69530368T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26605994A 1994-06-27 1994-06-27
US08/389,663 US5714163A (en) 1994-06-27 1995-02-16 Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
PCT/US1995/008037 WO1996000057A1 (en) 1994-06-27 1995-06-27 Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties

Publications (2)

Publication Number Publication Date
DE69530368D1 true DE69530368D1 (de) 2003-05-22
DE69530368T2 DE69530368T2 (de) 2003-12-18

Family

ID=26951608

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69530368T Expired - Lifetime DE69530368T2 (de) 1994-06-27 1995-06-27 Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung

Country Status (9)

Country Link
US (2) US5714163A (de)
EP (1) EP0734252B1 (de)
AT (1) ATE237311T1 (de)
AU (1) AU684209B2 (de)
CA (1) CA2191077C (de)
DE (1) DE69530368T2 (de)
DK (1) DK0734252T3 (de)
ES (1) ES2197919T3 (de)
WO (1) WO1996000057A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5876728A (en) * 1995-02-15 1999-03-02 Howard David Kass Natural composition extracted from plants used in the treatment of cancer
US5800833A (en) * 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
US6120800A (en) * 1997-09-25 2000-09-19 Nexstar Pharmaceuticals, Inc. Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
EP2266537B1 (de) * 1999-04-01 2014-09-03 Hana Biosciences, Inc. Zusammensetzungen zur Behandlung von Krebs
US7244450B2 (en) * 1999-04-01 2007-07-17 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6335023B1 (en) 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
US7452545B2 (en) * 2001-11-13 2008-11-18 Yu Ruey J Oligosaccharide aldonic acids and their topical use
EP1685843A1 (de) * 1999-06-30 2006-08-02 Ruey J. Dr. Yu Oligosaccharidealdonsäure und ihre topische Verabreichung
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU2002244247B2 (en) 2001-03-01 2007-12-13 Harbor Biosciences, Inc. Use of certain steroids for treatment of blood cell deficiencies
WO2002089772A1 (en) * 2001-05-09 2002-11-14 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
EP1807118B8 (de) 2004-09-29 2014-04-23 Harbor Therapeutics, Inc. Steroidanaloga sowie charakterisierungs- und behandlungsverfahren
US20070026061A1 (en) * 2005-05-25 2007-02-01 Nahid Ali Liposomal formulation and use thereof
EP1932517A3 (de) * 2006-12-11 2008-07-16 Universiteit Utrecht Holding B.V. Liposomen beinhaltend Polyphenolderivaten und deren Verfahren zur Nachbeladung
PL387296A1 (pl) * 2009-02-17 2010-08-30 Instytut Farmaceutyczny Sposób aktywnego zamykania amfifilowych substancji czynnych w strukturach liposomowych
US11458199B2 (en) * 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
KR102186116B1 (ko) 2012-11-20 2020-12-03 스펙트럼 파마슈티컬즈 인크 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
CN110381922A (zh) * 2017-01-18 2019-10-25 淡马锡生命科学研究院有限公司 超稳定脂质体增加对有丝分裂细胞的靶向作用
US10836788B2 (en) 2019-02-05 2020-11-17 SD Chem, Inc. Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1270198A (en) * 1984-08-08 1990-06-12 Marcel B. Bally Encapsulation of antineoplastic agents in liposomes
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
JPH0714865B2 (ja) * 1986-10-28 1995-02-22 武田薬品工業株式会社 リポソ−ム製剤およびその製造法
ES2068197T3 (es) * 1987-01-27 1995-04-16 Vestar Inc Vehiculo de liberacion a base de fosfolipidos para ingredientes activos insolubles en agua.
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
AU638271B2 (en) * 1989-06-22 1993-06-24 Nexstar Pharmaceuticals, Inc. Encapsulation process
US5322862A (en) * 1990-05-22 1994-06-21 Nippon Kayaku Kabushiki Kaisha Resin molding composition for preventing gnawing damage by animals
AU654835B2 (en) * 1991-07-03 1994-11-24 Nexstar Pharmaceuticals, Inc. Loading technique for preparing drug containing liposomes
EP0661044A1 (de) * 1991-07-03 1995-07-05 NeXstar Pharmaceuticals, Inc. Arzneistoff enthaltende Liposomen
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties

Also Published As

Publication number Publication date
DK0734252T3 (da) 2003-07-21
EP0734252B1 (de) 2003-04-16
CA2191077C (en) 2008-02-05
CA2191077A1 (en) 1996-01-04
DE69530368T2 (de) 2003-12-18
ES2197919T3 (es) 2004-01-16
AU684209B2 (en) 1997-12-04
AU2998495A (en) 1996-01-19
ATE237311T1 (de) 2003-05-15
EP0734252A1 (de) 1996-10-02
WO1996000057A1 (en) 1996-01-04
US5888537A (en) 1999-03-30
US5714163A (en) 1998-02-03

Similar Documents

Publication Publication Date Title
DE69530368D1 (de) Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung
ATE286718T1 (de) Temperatursensitive liposomale formulierung
CA2196780A1 (en) A liposomal delivery system comprising cationic lipopolyamines and neutral lipids for delivery of biologically active agents
CA2193502A1 (en) Sphingosomes for enhanced drug delivery
NZ503568A (en) Biphasic lipid vesicle composition for transdermal administration of an immunogen
AU4711296A (en) Method for loading lipid vesicles
CA1262334C (en) STEROID LIPOSOMES
AU3922193A (en) Liposome encapsulated taxol and a method of using the same
CA2168260A1 (en) Biphasic Multilamellar Lipid Vesicles
AU3559895A (en) Polyethylene glycol modified ceramide lipids and liposome uses thereof
AU5314194A (en) Cosmetic delivery system for salicylic acid and process for preparation of the same
IT1199967B (it) Liposomi contenenti interleucina,metodo per la loro preparazione e loro uso terapeutico nelle affezioni tumorali
ES2134846T3 (es) Formulacion de antibiotico y uso para infecciones resistentes a farmacos.
ATE260643T1 (de) System zur verabreichung makromolekularer wirkstoffe auf der basis von membran-mimetischen amphiphilen in aerosolform
ATE226843T1 (de) Mittel zur tumortherapie auf liposomenbasis, die tamoxifen enthalten
CA2326348A1 (en) Liposomal bupivacaine compositions and methods of preparation
ATE112679T1 (de) Wässrige bereitung von liposomenzusammensetzungen.
DE69520231D1 (de) Liposomzubereitungen enthaltend hybrid-interferon
ATE85890T1 (de) Liposome, ihre herstellung und anwendung als vektor von arzneimitteln.
DK1360958T3 (da) Liposomformulering af clobetasolpropionat
HK1041450A1 (zh) 脂质体合成物和放射致敏剂的施药方法
ES2130969A1 (es) Biomembranas para la encapsulacion extemporanea de tetracaina.
MX9708111A (es) Lipidos cationicos para terapia genica.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: HARWARDT NEUMANN MUELLER & PARTNER PATENTANWAELTE, 5